AU763232B2 - High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one - Google Patents

High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one Download PDF

Info

Publication number
AU763232B2
AU763232B2 AU62029/99A AU6202999A AU763232B2 AU 763232 B2 AU763232 B2 AU 763232B2 AU 62029/99 A AU62029/99 A AU 62029/99A AU 6202999 A AU6202999 A AU 6202999A AU 763232 B2 AU763232 B2 AU 763232B2
Authority
AU
Australia
Prior art keywords
hydroxy
methyl
pregn
amount
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU62029/99A
Other languages
English (en)
Other versions
AU6202999A (en
Inventor
Peter Huub Gerard Maria Kirchholtes
Gerard Arnoud Jozef Maria Theresia Sas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme BV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU763232(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of AU6202999A publication Critical patent/AU6202999A/en
Application granted granted Critical
Publication of AU763232B2 publication Critical patent/AU763232B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU62029/99A 1998-10-16 1999-10-11 High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one Expired AU763232B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98203460 1998-10-16
EP98203460 1998-10-16
PCT/EP1999/007768 WO2000023460A1 (en) 1998-10-16 1999-10-11 HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE

Publications (2)

Publication Number Publication Date
AU6202999A AU6202999A (en) 2000-05-08
AU763232B2 true AU763232B2 (en) 2003-07-17

Family

ID=8234220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62029/99A Expired AU763232B2 (en) 1998-10-16 1999-10-11 High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one

Country Status (30)

Country Link
US (3) US6969708B1 (pl)
EP (2) EP1121375B1 (pl)
JP (1) JP2002527525A (pl)
KR (3) KR100635018B1 (pl)
CN (2) CN100432093C (pl)
AR (1) AR020832A1 (pl)
AT (1) ATE239032T1 (pl)
AU (1) AU763232B2 (pl)
BR (1) BR9914441A (pl)
CA (1) CA2344686C (pl)
CO (1) CO5160271A1 (pl)
CZ (1) CZ298703B6 (pl)
DE (1) DE69907495T2 (pl)
DK (1) DK1121375T3 (pl)
ES (1) ES2197677T3 (pl)
HK (1) HK1039620B (pl)
HU (1) HUP0104206A3 (pl)
ID (1) ID28463A (pl)
IL (1) IL141850A (pl)
NO (1) NO317427B1 (pl)
NZ (1) NZ510501A (pl)
PE (1) PE20001377A1 (pl)
PL (1) PL197870B1 (pl)
PT (1) PT1121375E (pl)
RU (1) RU2220975C2 (pl)
SK (1) SK284569B6 (pl)
TR (2) TR200101083T2 (pl)
TW (2) TW200403251A (pl)
WO (1) WO2000023460A1 (pl)
ZA (1) ZA200101952B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356465A1 (pl) * 2002-10-04 2004-04-05 ANPHARM Przedsiębiorstwo Farmaceutyczne S.A. Sposób wytwarzania 17beta-hydroksy-7alfa-metylo-19-nor-17alfa-pregn-5(10)-en-20-yn-3-onu
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
LT2662380T (lt) * 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
EP2610261A1 (en) 2005-02-01 2013-07-03 F. Hoffmann-La Roche AG Ibandronate polymorph B
EP1883648A1 (en) * 2005-05-23 2008-02-06 Newchem S.p.A. Process for the preparation of pure crystalline tibolone
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
ITMI20130120A1 (it) * 2013-01-25 2014-07-26 Ind Chimica Srl Processo per la preparazione in forma cristallina di tibolone, (7alfa,17alfa)-17-idrossi-7-metil-19-norpregn-5(10)-en-20-in-3-one
AU2019401576A1 (en) * 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CN114409717B (zh) * 2021-12-17 2023-03-17 湖南科益新生物医药有限公司 替勃龙中间体醚化物和替勃龙的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389035A1 (en) * 1989-03-18 1990-09-26 Akzo Nobel N.V. Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE665514A (pl) * 1964-06-16
CH488682A (de) * 1965-07-30 1970-04-15 Ciba Geigy Verfahren zur Herstellung von 4,9,11-Trienen der 19-Nor-androstanreihe
NL146838B (nl) * 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
US3515719A (en) * 1967-03-15 1970-06-02 Upjohn Co 7-methyl-6,19-epoxy steroids of the androstane series
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
EP0406279A1 (en) * 1988-03-25 1991-01-09 Akzo N.V. Pharmaceutical preparation containing a fluoride salt
EP0613687B1 (en) * 1993-03-05 1999-06-02 Akzo Nobel N.V. Use of a pregnane derivatives for the treatment of tumours
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
IL123422A (en) * 1997-03-05 2003-05-29 Akzo Nobel Nv USE OF 7alpha-METHYL-17alpha-ETHYNYL-ESTRANE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR THE TREATMENT OF ATHEROSCLEROSIS
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389035A1 (en) * 1989-03-18 1990-09-26 Akzo Nobel N.V. Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one

Also Published As

Publication number Publication date
ID28463A (id) 2001-05-24
CA2344686A1 (en) 2000-04-27
NO20011664L (no) 2001-04-03
CO5160271A1 (es) 2002-05-30
US20050245496A1 (en) 2005-11-03
PT1121375E (pt) 2003-07-31
DE69907495T2 (de) 2004-05-06
CN1322210A (zh) 2001-11-14
HUP0104206A2 (hu) 2002-04-29
EP1275379A2 (en) 2003-01-15
BR9914441A (pt) 2001-06-26
CN1769293A (zh) 2006-05-10
ATE239032T1 (de) 2003-05-15
NO317427B1 (no) 2004-10-25
CN100432093C (zh) 2008-11-12
CZ2001976A3 (cs) 2001-08-15
NZ510501A (en) 2003-10-31
PL347264A1 (en) 2002-03-25
CZ298703B6 (cs) 2007-12-27
JP2002527525A (ja) 2002-08-27
AR020832A1 (es) 2002-05-29
HUP0104206A3 (en) 2002-06-28
IL141850A (en) 2005-11-20
US6969708B1 (en) 2005-11-29
EP1275379A3 (en) 2003-03-26
EP1121375A1 (en) 2001-08-08
KR20060071897A (ko) 2006-06-27
KR100635018B1 (ko) 2006-10-17
RU2220975C2 (ru) 2004-01-10
TW200403251A (en) 2004-03-01
SK4932001A3 (en) 2001-12-03
TW577893B (en) 2004-03-01
PL197870B1 (pl) 2008-05-30
CN100378116C (zh) 2008-04-02
CA2344686C (en) 2009-04-28
ZA200101952B (en) 2002-06-10
KR20010080133A (ko) 2001-08-22
HK1039620B (en) 2003-08-22
SK284569B6 (sk) 2005-06-02
WO2000023460A1 (en) 2000-04-27
PE20001377A1 (es) 2000-12-09
KR20050003358A (ko) 2005-01-10
NO20011664D0 (no) 2001-04-03
AU6202999A (en) 2000-05-08
EP1121375B1 (en) 2003-05-02
US20040248870A1 (en) 2004-12-09
TR200101083T2 (tr) 2001-08-21
DK1121375T3 (da) 2003-08-04
HK1039620A1 (en) 2002-05-03
TR200504091T2 (tr) 2006-05-22
ES2197677T3 (es) 2004-01-01
IL141850A0 (en) 2002-03-10
DE69907495D1 (de) 2003-06-05

Similar Documents

Publication Publication Date Title
AU2002227421B2 (en) Steroid hormone products comprising a stabilizing agent in non-crystalline form
RU2166936C2 (ru) Способ получения дозировочных единиц путем мокрой грануляции
EP1121375B1 (en) High purity compound (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
RU2207133C2 (ru) Стабилизированные композиции тиболона
MXPA01003797A (en) HIGH PURITY COMPOSITION COMPRISING (7&agr;,17&agr;)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE
WO2009012733A2 (en) Method of manufacture of compressed pharmaceutical formulation containing tibolone
JP2005529929A (ja) プロゲスターゲン投与単位
CZ374299A3 (cs) Farmaceutická léková forma
WO2005084682A1 (en) Pharmaceutical composition comprising cyclodextrin complex of tibolone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired